Edition:
United Kingdom

People: Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
$1.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,247
52-wk High
$4.80
52-wk Low
$0.69

Mehta, Ketan 

Mr. Ketan Bhupatrai Mehta is Director of the company. Mr. Mehta, a pharmaceutical scientist by education, is the Founder and Chief Executive Officer of Tris Pharma, a fully-integrated specialty pharmaceutical company focused on developing and commercializing advanced delivery technologies. Mr. Mehta founded Tris in 2000 and has built the company into a leading specialty pharmaceutical company with over 500 employees. Tris develops, manufactures, licenses, and commercializes both branded and generic pharmaceuticals directly and through commercial partnerships with both large and emerging pharmaceutical companies. Tris has developed many pharmaceutical technologies, including its extended-release platform LiquiXR® and holds over 150 patents in the U.S. and around the world. Before founding Tris Pharma, Mr. Mehta worked for Capsugel (formerly a division of Pfizer) in sales, marketing and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Mr. Mehta holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --